Neurohormonal responses to D-fenfluramine in healthy elderly subjects. A placebo-controlled study

Psychoneuroendocrinology

Volumn 25, Issue 2, 2000, Pages 139-150

  Ramasubbu, Rajamannar ^a   Flint, Alastair ^b   Brown, Gregory ^b   Awad, George ^b   Kennedy, Sidney ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cortisol; D fenfluramine; Elderly; Prolactin; Serotonin

Indexed keywords

DEXFENFLURAMINE; HYDROCORTISONE; NORFENFLURAMINE; PLACEBO; PROLACTIN;

ADULT; AGE; AGED; ARTICLE; BEHAVIOR; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENDER; HEART ARRHYTHMIA; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; MALE; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROVOCATION TEST; SEROTONINERGIC TRANSMISSION; SINGLE BLIND PROCEDURE; TOPICAL DRUG ADMINISTRATION; VERTIGO; VOLUNTEER;

AGED; AGED, 80 AND OVER; AGING; BEHAVIOR; BODY WEIGHT; FEMALE; FENFLURAMINE; HEMODYNAMIC PROCESSES; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PROLACTIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS;

EID: 0033991334     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(99)00044-X     Document Type: Article

References (25)

1. Campbell D.B. Dexfenfluramine: an overview of its mechanisms of action. Rev. Contemp. Pharmacother. 2:1991;93-113.
2. Coccaro E.F., Kavoussi R.J., Hauger R. PRL and HVA responses to D- and D,L-fenfluramine in humans. Biol. Psychiatry. 35:1994;615-747.
3. Costa E.A., Groppetti A., Refuelta A. Action of fenfluramine on monoamine stores of rat tissue. Br. J. Pharmacol. 41:1971;57-64.
4. Fuxe K., Farnebo L.O., Hamberger B., Ogren S.O. On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, especially 5 hydroxytryptamine neurons and their relation to the anorectic activity of fenfluramine. Postgrad. Med. J. 551:1975;35-45.
5. Gorard D.A., Taylor T.M., Medbak S.H., Perry L.A., Libby G.W., Farthing M.J. Plasma prolactin, adrenocorticotrophic hormone, and cortisol after administration of D-fenfluramine or placebo to healthy subjects. Int. Clin. Psychopharmacol. 8:1993;123-128.
6. Goodwin G.M., Murray C.L., Bancroft J. Oral D-fenfluramine and neuroendocrine challenge: problems with the 30 mg dose in men. J. Affect. Disord. 30:1994;117-122.
7. Guy-Grand B.J.P., Crepaldi G., Lefebvre P., Apfelbaum M., Gries A., Turner P. International trial of long-term dexfenfluramine in obesity. Lancet. ii:1989;1142-1145.
8. Invernizzi R., Bertorelli R., Consolo S., Garattini S., Samanin R. The effects of the L-isomer of fenfluramine and dopamine mechanism in rat brain. Eur. J. Pharmacol. 164:1989;241-248.
9. Kerbs H.A., Cheng L.K., Wright G.S. Determination of fenfluramine and nor-fenfluramine in plasma using a nitrogen sensitive detector. J. Chromatr. Biomed. Appl. 310:1984;412-417.
10. Maes M., D'Hondt P., Suy E., Minner B., Vandervorst C., Raus J. HPA-axis hormones and prolactin responses to dextro-fenfluramine in depressed patients and healthy controls. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 15:1991;781-790.
11. Marcusson J., Oreland L., Winblad B. Effect of age on human brain serotonin (S1) binding sites. J. Neurochem. 43:1984;1699-1705.
12. Marcusson J., Morgan D.G., Winbaild B., Finch C.E. Serotonin-2 binding sites in human frontal cortex and hippocampus. Selective loss of S-2A sites with age. Brain Res. 311:1984;51-56.
13. McBride P.A., Tierney H., DeMeo M., Chen J.S., Mann J.J. Effect of age and gender on CNS serotonergic responsivity in normal adults. Biol. Psychiatry. 27:1990;1143-1155.
14. Muldoon M.F., Manuck S.B., Jansma C.L., Moore A.L., Perel J., Mann J.J. D,L-fenfluramine challenge test: experience in nonpatient sample. Biol. Psychiatry. 39:1996;761-768.
15. O'Keane V., Dinan T.G. Prolactin and cortisol responses to D-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am. J. Psychiatry. 148:1991;1009-1015.
16. O'Keane V., O'Hanlon M., Webb M., Dinan T. D-fenfluramine/prolactin responses throughout the menstural cycle: evidence for an oestrogen-induced alteration. Clin. Endocrinol. 34:1991;289-292.
17. Quattrone A., Tedeschri G., Aguglia U., Scopacasa F., Direnzo G.F., AnnunZiato L. Prolactin secretion in man: a useful to evaluate activity of drugs on central 5-hydroxy tryptaminergic neurones. Studies with fenfluramine. Br. J. Clin. Pharmacol. 16:1983;471-475.
18. Rittanhouse P.T., Bakkum E.A., Herbert G., Betha C.L., Van de Kar L.D. Serotonin receptor subtypes mediating neuroendocrine responses to DOI. Pharmacologist. 32:1990;185.
19. Ritson E.B., Chick J.D. Kendell R.E., Zealley A.K. Dependence on Alcohol and Other Drugs Comparison to Psychiatric Studies. 1988;476-504 Churchill Livingstone, Edinburgh.
20. Silverstone T., Smith G., Richards R. A comparative evaluation of dextrofenfluramine and dl-fenfluramine. Bender A.F., Brooks L.J. Bodyweight Control: The Physiology, Clinical Treatment and Prevention of Obesity. 1987;240-246 Churchill Livingstone, Edinburgh.
21. Thompson P.A., Maes M., Meltzer H.Y. Effect of the placebo control condition in neuroendocrine challenge studies. Psychiatry Res. 52:1994;317-326.
22. Van de Kar L.D., Urban J.H., Richardson K.D., Bethea C.L. Pharmacological studies on the serotonergic and nonserotonin-mediated stimulation of prolactin and corticosterone secretion by fenfluramine. Neuroendocronology. 41:1985;283-288.
23. Van de Kar L.D. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annu. Rev. Pharmacol. Toxicol. 31:1991;289-320.
24. Williams G.H. Hypertensive vascular disease. Isselbacher K.J., Braunwald E., Wilson J.D., Martin J.V., Fauci A.S., Kasper D.L. Harrison's Principles of Internal Medicine. 13th edn:1994;1116-1131 McGraw Hill, USA.
25. Yatham L.N., Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sci. 53:1993;447-463.